← Back to Screener
Fortrea Holdings Inc. Common Stock (FTRE)
Price$15.76
Value ScoreB
Growth ScoreF
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)37.36%
Price vs S&P 500 (4W)21.38%
VGM Score57.31
Market Capitalization$1.46B
All Metrics
P/CF (Annual)12.83x
Book Value / Share (Quarterly)$5.56
P/TBV (Annual)2.37x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-4.19%
Cash Flow / Share (Quarterly)$2.01
Price vs S&P 500 (YTD)-21.72%
Gross Margin (TTM)18.86%
Net Profit Margin (TTM)-16.50%
EPS (TTM)$-4.91
10-Day Avg Trading Volume1.13M
EPS Excl Extra (TTM)$-4.91
Revenue Growth (5Y)1.09%
EPS (Annual)$-10.81
ROI (Annual)-61.02%
Gross Margin (Annual)18.50%
Net Profit Margin (5Y Avg)-7.95%
Cash / Share (Quarterly)$1.56
Revenue Growth QoQ (YoY)-2.27%
ROA (Last FY)-36.31%
Revenue Growth TTM (YoY)0.86%
EBITD / Share (TTM)$-2.99
ROE (5Y Avg)-38.36%
Operating Margin (TTM)-13.14%
Cash Flow / Share (Annual)$0.95
P/B Ratio2.77x
P/B Ratio (Quarterly)1.67x
Net Income / Employee (Annual)$-69,000
EV / Revenue (TTM)0.87x
Net Interest Coverage (TTM)-7.31x
ROA (TTM)-16.29%
EV / EBITDA (TTM)347.34x
EPS Incl Extra (Annual)$-10.81
Current Ratio (Annual)0.98x
Quick Ratio (Quarterly)0.83x
3-Month Avg Trading Volume1.53M
52-Week Price Return268.18%
EV / Free Cash Flow (Annual)26.75x
Revenue / Employee (TTM)$189,400
Tangible BV / Share (Quarterly)$2.29
P/S Ratio (Annual)0.53x
Asset Turnover (Annual)1.00x
52-Week High$18.67
Operating Margin (5Y Avg)-5.13%
EPS Excl Extra (Annual)$-10.81
CapEx CAGR (5Y)0.98%
26-Week Price Return53.29%
Quick Ratio (Annual)0.91x
13-Week Price Return42.50%
Total Debt / Equity (Annual)1.87x
Current Ratio (Quarterly)0.95x
Enterprise Value$2.36B
Revenue / Share Growth (5Y)0.50%
Asset Turnover (TTM)0.99x
Revenue / Employee (Annual)$190,400
Pretax Margin (Annual)-36.09%
Cash / Share (Annual)$1.88
3-Month Return Std Dev70.46%
Gross Margin (5Y Avg)19.61%
Net Income / Employee (TTM)$-31,300
ROE (Last FY)-175.01%
Net Interest Coverage (Annual)-3.48x
EPS Basic Excl Extra (Annual)$-10.81
P/FCF (TTM)6.76x
Receivables Turnover (TTM)4.02x
EV / Free Cash Flow (TTM)12.40x
Total Debt / Equity (Quarterly)2.00x
EPS Incl Extra (TTM)$-4.91
Receivables Turnover (Annual)4.36x
ROI (TTM)-26.81%
P/S Ratio (TTM)0.54x
Pretax Margin (5Y Avg)-7.03%
Revenue / Share (Annual)$29.86
Tangible BV / Share (Annual)$7.88
Forward P/E17.34x
Free OCF CAGR (5Y)-12.97%
Price vs S&P 500 (52W)239.98%
Year-to-Date Return-10.78%
5-Day Price Return16.41%
EPS Normalized (Annual)$-10.81
ROA (5Y Avg)-7.87%
Net Profit Margin (Annual)-36.21%
Month-to-Date Return33.83%
EBITD / Share (Annual)$-8.71
Operating Margin (Annual)-32.04%
LT Debt / Equity (Annual)1.86x
P/CF (TTM)6.60x
ROI (5Y Avg)-13.24%
LT Debt / Equity (Quarterly)1.98x
EPS Basic Excl Extra (TTM)$-4.91
P/TBV (Quarterly)3.29x
P/B Ratio (Annual)2.83x
Pretax Margin (TTM)-16.51%
Book Value / Share (Annual)$6.05
Price vs S&P 500 (13W)32.75%
Beta2.15x
P/FCF (Annual)16.49x
Revenue / Share (TTM)$28.94
ROE (TTM)-79.12%
52-Week Low$3.97
vGradeB
gGradeF
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.16est. 0.05
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.65
3.71
3.76
3.76
Industry Peers — Health Services(28)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FTREFortrea Holdings Inc. Common Stock | B | F | A | $15.76 |
| NTRANatera, Inc. Common Stock | F | A | B | $218.81 |
| DGXQuest Diagnostics Inc. | C | D | C | $192.20 |
| LHLabcorp Holdings Inc. | C | D | C | $256.87 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $129.14 |
| CELCCelcuity Inc. Common Stock | — | — | B | $122.96 |
| CAICaris Life Sciences, Inc. Common Stock | F | F | C | $16.45 |
| RDNTRadNet, Inc. Common Stock | D | C | D | $52.89 |
| VCYTVeracyte, Inc. | D | A | B | $48.18 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $64.40 |
About
Fortrea is a global contract research organization providing comprehensive clinical trial management, pharmacology, and patient access solutions for biopharma, medical device, and diagnostic companies. The company offers flexible engagement models ranging from functional services to full-service trial management. Spun off from Labcorp in 2023, Fortrea operates as an independent public company with approximately 19,000 employees across 90 countries.